



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Assessment of the Value of Mean Platelet Volume, Des Gamma Carboxy Prothrombin and Alpha Feto Protein in Early Detection of HCC

A Thesis

Submitted for Partial Fulfillment of
master degree in **Internal Medicine**

By

Omnia Ahmed Ellaithy

M.B.B.C.H.,

Under Supervision of

Prof. Dr. Kadry Mohamed El Saeed

*Professor of Hepatology, Gastroenterology and Internal
Medicine,*

Faculty of Medicine - Ain Shams University

Prof. Dr. Nevine Ibrahim Musa

*Professor of Hepatology, Gastroenterology and Internal
Medicine,*

Faculty of Medicine - Ain Shams University

Dr. Shaimaa Hussien GadAllah

*Lecturer of Hepatology, Gastroenterology and Internal Medicine,
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University
2021**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the
Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and
profound gratitude to **Prof. Dr. Kadry Mohamed El
Saeed**, Professor of Hepatology, Gastroenterology and
Internal Medicine, - Faculty of Medicine- Ain Shams
University for his keen guidance, kind supervision,
valuable advice and continuous encouragement, which
made possible the completion of this work.*

*I am also delighted to express my deepest
gratitude and thanks to **Prof. Dr. Nevine Ibrahim
Musa**, Professor of Hepatology, Gastroenterology and
Internal Medicine,, Faculty of Medicine, Ain Shams
University, for her kind care, continuous supervision,
valuable instructions, constant help and great
assistance throughout this work.*

*I am deeply thankful to **Dr. Shaimaa Hussien
GadAllah**, Lecturer of Hepatology, Gastroenterology
and Internal Medicine, Faculty of Medicine, Ain Shams
University, for her great help, active participation and
guidance.*

*I would like to express my hearty thanks to all
my family for their support till this work was completed.*

*Last but not least my sincere thanks and
appreciation to all patients participated in this study.*

Omnia Ahmed Ellaithy

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iv
Introduction.....	1
Aim of the Work	7
Review of Literature	
Basics, Clinical Picture of HCC	8
Diagnosis and Treatment of HCC.....	25
Platelet Count (PC), Mean Platelet Volume (MPV), PC/MPV Ratio.....	64
Patients and Methods.....	102
Results.....	111
Discussion.....	125
Summary.....	135
Conclusion	138
Recommendations.....	139
References.....	140
Arabic Summary	---

List of Tables

Table No.	Title	Page No.
Table (1):	Sixth edition UICC TNM classification of HCC (2002).....	48
Table (2):	Modified Sixth edition TNM classification of HCC (is simplified into 4 stages to represent the optimum prognostic prediction).....	49
Table (3):	OKUDA Staging System	50
Table (4):	CUPI score Error! Bookmark not defined.	
Table (5):	CLIP scoring system	52
Table (6):	Several methods of locoregional treatment of HCC:	56
Table (7):	Increased MPV in various diseases.....	66
Table (8):	Key platelet components and their contribution to hemostasis and malignancy.....	78
Table (9):	Demographic characteristics among the studied groups.....	111
Table (10):	Liver condition among the HCC and CLD groups	112
Table (11):	Radiological findings among the studied groups.....	112
Table (12):	Focasl lesion characteristics among HCC group	114
Table (13):	Laboratory findings among the studied groups.....	115
Table (14):	Tumor markers among the studied groups.....	117
Table (15):	Diagnostic performance of tumor markers in differentiating HCC from CLD groups.....	120
Table (16):	Diagnostic characteristics of tumor markers cutpoints in differentiating HCC from CLD	121
Table (17):	Diagnostic characteristics of AFP and DCP cutpoints in differentiating HCC from CLD	123

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Causes and etiology of Non –cirrhotic HCC	10
Figure (2):	Natural history and biological drivers of HCV-induced HCC development.....	15
Figure (3):	Growth patterns of progressed hepatocellular carcinoma.	19
Figure (4):	Surveillance imaging in adults at risk for hepatocellular carcinoma.....	26
Figure (5):	Various gray scale US features of HCCs.....	41
Figure (6):	CT scans for a liver showing (A) arterial enhancement and (B) portal venous washout	43
Figure (7):	Demonstrates an isointense lesion in segment VIII on precontrast T1-weighted 3D (a), which shows enhancement on the arterial phase (b) and washout on the delayed phase (c) with an enhancing capsule. Mildly increased signal is observed on T2-weighted nonfat- saturated single-shot images (d); all these features are characteristic of HCC	44
Figure (8):	Celiac angiography revealed a hyper vascular tumor with proliferation of fine tumor vessels (which also showed nodular and mosaic features) at the S4/8 region of the liver, just below the dome of right diaphragm	46
Figure (9):	BCLC staging system	51
Figure (10):	The JIS score can be obtained by summing up the TNM stage score (stages I, II, III, and IV are allocated to scores 0, 1, 2, and 3, respectively) and Child-Turcotte-Pugh stage score (stages A, B, and C are allocated to scores 0, 1, and 2, respectively).....	52

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (11):	Modified BCLC staging classification and treatment schedule	53
Figure (12):	The interaction between platelets and different cells in the tumor and stromal compartments of hepatocellular carcinoma (HCC).	72
Figure (13):	Platelets are involved in key steps of malignancy progression.....	79
Figure (14):	Overview of different anti-platelet therapies currently tested in preclinical and clinical studies for hepatocellular carcinoma (HCC) and other types of cancer	100
Figure (15):	(Danila, 2014)	105
Figure (16):	(Garg et al., 2019)	106
Figure (17):	AFP among the studied groups.....	118
Figure (18):	MPV among the studied groups	118
Figure (19):	DCP among the studied groups	119
Figure (20):	ROC curve for tumor markers in differentiating HCC from CLD groups	120
Figure (21):	Diagnostic characteristics of tumor markers cutpoints in differentiating HCC from CLD.....	122
Figure (22):	Diagnostic characteristics of AFP and DCP cutpoints in differentiating HCC from CLD.....	124

List of Abbreviations

Abb.	Full term
<i>AFP</i>	<i>Alpha-fetoprotein</i>
<i>AFU</i>	<i>Alpha L-Fucosidase</i>
<i>AJCC</i>	<i>American Joint Committee on Cancer</i>
<i>ALT</i>	<i>Alanine aminotransferase</i>
<i>AST</i>	<i>Aspartate aminotransferase</i>
<i>BCLC</i>	<i>Barcelona Clinic Liver Cancer</i>
<i>CEUS</i>	<i>Contrast enhanced ultrasound</i>
<i>CLD</i>	<i>Chronic liver disease</i>
<i>CT</i>	<i>Computed Tomography</i>
<i>CUPI</i>	<i>Chinese University Prognostic Index</i>
<i>DAA</i>	<i>Direct-acting antivirals</i>
<i>DGP</i>	<i>Des-γ-carboxy prothrombin</i>
<i>DMSA</i>	<i>Dimercaptosuccinic acid</i>
<i>DWI</i>	<i>Diffusion-weighted</i>
<i>EPO</i>	<i>Erythropoietin</i>
<i>EUS</i>	<i>Endoscopic US</i>
<i>HBV</i>	<i>Hepatitis B virus</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>
<i>HCV</i>	<i>hepatitis C virus</i>
<i>HSP</i>	<i>Heat shock protein</i>
<i>IGF-II</i>	<i>Insulin-like growth factor-II</i>
<i>IL 8</i>	<i>Interleukin-8</i>
<i>IOUS</i>	<i>Intra-operative US</i>
<i>IR</i>	<i>Insulin resistance</i>
<i>JIS</i>	<i>Japan Integrated Staging</i>
<i>LA</i>	<i>Laser ablation</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>MAGE</i>	<i>Melanoma antigen gene</i>
<i>MC</i>	<i>Milan criteria</i>
<i>MCT</i>	<i>Microwave coagulation therapy</i>
<i>MPC</i>	<i>Mean platelet component</i>
<i>MPV</i>	<i>Mean platelet volume</i>
<i>MR</i>	<i>Magnetic resonance</i>
<i>MRI</i>	<i>Magnetic resonance Imaging</i>
<i>PBC</i>	<i>Primary biliary cirrhosis</i>
<i>PEI</i>	<i>Percutaneous Ethanol injection</i>
<i>PET</i>	<i>Positron Emission Tomography</i>
<i>RFA</i>	<i>Radiofrequency Thermal Ablation</i>
<i>SCCA</i>	<i>Serum squamous cell carcinoma antigen</i>
<i>TACE</i>	<i>Transarterial chemoembolization</i>
<i>TAE</i>	<i>Transarterial embolization</i>
<i>TGF-β1</i>	<i>Transforming growth factor-beta 1</i>
<i>TNM</i>	<i>Tumor-Node-Metastasis Staging System</i>
<i>TNM</i>	<i>Tumor-Node-Metastasis Staging System</i>
<i>UICC</i>	<i>Union International Contre le Cancer</i>
<i>US</i>	<i>Role of Ultrasound</i>
<i>VEGF</i>	<i>Vascular endothelial growth factor</i>
<i>WHO</i>	<i>World Health Organization</i>

ABSTRACT

Background: Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. AFP is the gold standard tumor marker for HCC, mean platelet volume (MPV) is a parameter obtained from complete blood count (CBC) by automated analyzers, shown to be increased in multiple malignancies and inflammatory conditions. This cross sectional comparative study was designed to evaluate the diagnostic usefulness of MPV as a diagnostic marker in HCC patients due to cirrhosis.

Aim of the Work: To determine the value of mean platelet volume, Des gamma Carboxy prothrombin and Alfa-feto protein in early detection of Hepatocellular carcinoma

Patients and Methods: 105 patients were enrolled in this study, they were divided into 3 equal groups **Group A:** Hepatocellular carcinoma patients (HCC) **Group B:** Liver cirrhosis patients **Group C:** Healthy Control group each is 35 patients. MPV, AFP, DCP were evaluated in all groups. Ultrasound and Triphasic CT. were also done to Group A&B to confirm or exclude the diagnosis of HCC and in group C as they are candidates for LDLT donors.

Results: Our results showed that regarding the diagnostic performance of the three tested tumor markers (AFP, MPV and DCP) in differentiating HCC from CLD groups that AFP had area under curve (AUC) of 0.719, Standard error (SE) of 0.061, Confidence interval (CI) of 0.599-0.839 and P value of 0.002 at a cut point of ≥ 40.0 , MPV had area under curve (AUC) of 0.801, Standard error (SE) of 0.063, Confidence interval (CI) of 0.678–0.924 and P value of <0.001 at a cut point of ≥ 10.2 , while DCP had area under curve (AUC) of 0.842, Standard error (SE) of 0.047, Confidence interval (CI) of 0.750–0.935 and P value of <0.001 at a cut point of ≥ 69.3 proving that DCP had the highest significant diagnostic performance in differentiating HCC from CLD groups also DCP ≥ 69.3 had highest sensitivity (of 97.1%) and NPV (of 96.3%). AFP ≥ 40.0 had highest specificity (of 91.4%) and PPV (of 86.4%).

Conclusion: Measurement of MPV is non-invasive, cheap and quick, and may therefore serve as a predictor of HCC in patients with CLD. Low sensitivity and specificity, on the other hand, suggests that this may be an adjunctive parameter to some other markers like AFP. Further studies with larger samples are needed to determine the association of MPV with HCC. For a single test DCP had highest significant diagnostic performance in differentiating HCC from CLD groups. In detection of HCC testing AFP ≥ 40.0 if positive considered positive. If negative, retest for DCP ≥ 69.3 if positive considered positive, otherwise is negative. This although decreased specificity and Positive predictive value, it raised sensitivity and Negative Predictive Value to 100.0% when combining both AFP and DCP. The benefit of increasing the sensitivity is not to miss cases with HCC while the decreased specificity and PPV can be compensated by further imaging studies to eliminate the false positive cases.

Keywords: Value of Mean Platelet Volume, Des Gamma Carboxy Prothrombin, Alpha Feto Protein, HCC

INTRODUCTION

Primary liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer mortality worldwide, with an estimated 841,000 cases (9.3 cases per 100,000 person-years) and 782,000 deaths (8.5 deaths per 100,000 person-years) in 2018 (**Bray et al., 2018**).

HCC being often associated with liver cirrhosis masks symptoms of cancer progression and thus the clinical course of HCC is mostly asymptomatic (**Kurt et al., 2012**).

The incidence rate of HCC rises in accordance with increased rates of hepatitis C virus and hepatitis B virus infection (**El-Serag et al., 2010**). Aflatoxin exposure, heavy alcohol drinking, nonalcoholic fatty liver disease, and smoking also contribute to the occurrence and progression of HCC (**El-Serag et al., 2010**).

While the survival of patients with most malignancies has improved over the last decade, the prognosis of HCC remains poor, and most patients have a 5-years survival rate of less than 5% mainly because of the late diagnosis of more than two-thirds of patients diagnosed at advanced stages of disease (**Chen et al., 2009**). Although liver resection for early HCC could improve 5-year survival to 60–70% (**Forner et al., 2012**).

This worse outcome is due partly to the lack of an effective method for timely diagnosis, which leads to only 30–40% of HCC being suitable for potentially curative treatments at the time of diagnosis (**Llovet et al., 2008**).

Thus, surveillance of populations at-risk may detect tumors at an early stage when curative interventions can be implemented **(Lok et al., 2010)**. Several studies reported a benefit of HCC surveillance on survival and guidelines from professional organizations recommend HCC surveillance for at-risk populations **(Lok et al., 2010)**.

Two definitions of HCC were adopted as described previously, one for “definite” HCC and one for “presumed” HCC **(Lok et al., 2010)**

Definite HCC was defined by histologic confirmation or a new mass lesion on imaging with AFP levels increasing to >1,000 ng/mL **(Lok et al., 2010)**.

Presumed HCC was defined as a new mass lesion on ultrasound in the absence of histology and AFP <1,000 ng/mL in conjunction with one of the following characteristics: a) 2 liver imaging studies showing a mass lesion with characteristics of HCC (arterial enhancement $\pm$ wash out), b) progressively enlarging lesion on ultrasound leading to death, or c) 1 additional imaging study showing a mass lesion with characteristics of HCC that either increased in size over time or was accompanied by AFP level >200 ng/mL and more than tripling of baseline value **(Lok et al., 2010)**.

A major problem with HCC surveillance is the lack of reliable biomarkers. Alpha fetoprotein (AFP) is the most widely used biomarker for HCC surveillance; and was first introduced as a serological marker for HCC in the 1960s **(Price et al., 2020)**.